
AU  - Baird, Geoffrey S.
AU  - Montine, Thomas J.
C7  - pp. 170-180
TI  - Clinical Laboratory Investigations in Geriatric Neurology
SN  - 9781118730683
UR  - https://doi.org/10.1002/9781118730676.ch8
DO  - doi:10.1002/9781118730676.ch8
SP  - 170-180
KW  - cerebrovascular disorders infarction
KW  - clinical laboratory investigations
KW  - dementias
KW  - geriatric neurology
KW  - movement disorders
PY  - 2014
AB  - Summary Body fluids (blood, urine, cerebrospinal fluid) are preferred samples for neurological testing. This chapter focuses on the clinical laboratory examinations used to screen, diagnose, predict, and monitor neurologic disorders in geriatric patients. As the goals of laboratory testing in this population overlap those of general laboratory testing, a brief section on test interpretation and general laboratory considerations precedes the sections devoted to neurologic disorders of geriatric patients. The neurologic disorders for which laboratory investigations are described in the chapter are: dementias (Alzheimer's disease and Lewy body disease), movement disorders (Parkinson's disease and Parkinson-plus syndromes), cerebrovascular disorders (infarction and hemorrhage), and other disorders such as headache and depression.
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Anaesthesia
JA  - Anaesthesia
VL  - 74
IS  - S3
SN  - 9781118730683
UR  - https://doi.org/10.1111/anae.14740
DO  - doi:10.1111/anae.14740
SP  - 10
EP  - 95
PY  - 2019
ER  - 

TY  - JOUR
TI  - Poster Sessions
JO  - Epilepsia
VL  - 43
IS  - S8
SN  - 9781118730683
UR  - https://doi.org/10.1111/j.1528-1167.2002.tb06320.x
DO  - doi:10.1111/j.1528-1167.2002.tb06320.x
SP  - 65
EP  - 207
PY  - 2002
ER  - 

TY  - JOUR
TI  - Abstracts of the 37th Annual Scientific Meeting of the Indonesian Urological Association
JO  - BJU International
JA  - BJU Int
VL  - 114
IS  - S3
SN  - 9781118730683
UR  - https://doi.org/10.1111/bju.12921
DO  - doi:10.1111/bju.12921
SP  - 1
EP  - 24
PY  - 2014
ER  - 

TY  - JOUR
TI  - E-Posters
JO  - BJS (British Journal of Surgery)
JA  - Br J Surg
VL  - 106
IS  - S5
SN  - 9781118730683
UR  - https://doi.org/10.1002/bjs.11342
DO  - doi:10.1002/bjs.11342
SP  - 85
EP  - 128
PY  - 2019
ER  - 

TY  - JOUR
TI  - Abstracts–Symposia
JO  - Alcoholism: Clinical and Experimental Research
JA  - Alcohol Clin Exp Res
VL  - 37
IS  - s2
SN  - 9781118730683
UR  - https://doi.org/10.1111/acer.12163
DO  - doi:10.1111/acer.12163
SP  - 254A
EP  - 308A
PY  - 2013
ER  - 

TY  - JOUR
TI  - 2012 Annual Meeting Sunday, October 7, 2012 Poster Session Abstracts
JO  - Annals of Neurology
JA  - Ann Neurol.
VL  - 72
IS  - S16
SN  - 9781118730683
UR  - https://doi.org/10.1002/ana.23769
DO  - doi:10.1002/ana.23769
SP  - S1
EP  - S120
PY  - 2012
ER  - 

TY  - JOUR
TI  - Abstracts of The Movement Disorder Society's Eleventh International Congress of Parkinson's Disease and Movement Disorders
JO  - Movement Disorders
JA  - Mov. Disord.
VL  - 22
IS  - S16
SN  - 9781118730683
UR  - https://doi.org/10.1002/mds.21535
DO  - doi:10.1002/mds.21535
SP  - S1
EP  - S325
PY  - 2007
ER  - 

TY  - JOUR
TI  - Poster Session 1, Sunday 26 September
JO  - European Journal of Neurology
VL  - 17
IS  - s3
SN  - 9781118730683
UR  - https://doi.org/10.1111/j.1468-1331.2010.03232.x
DO  - doi:10.1111/j.1468-1331.2010.03232.x
SP  - 72
EP  - 350
PY  - 2010
ER  - 

TY  - JOUR
TI  - POSTER PRESENTATIONS
JO  - The Journal of Sexual Medicine
VL  - 6
IS  - s5
SN  - 9781118730683
UR  - https://doi.org/10.1111/j.1743-6109.2009.01608_3.x
DO  - doi:10.1111/j.1743-6109.2009.01608_3.x
SP  - 429
EP  - 479
PY  - 2009
ER  - 

AU  - Gunaga, K. P.
AU  - Gunaga, Satheesh
C7  - pp. 125-141
TI  - Laboratory Diagnosis of Addicting Drugs
SN  - 9780470740330
UR  - https://doi.org/10.1002/9780470710449.ch8
DO  - doi:10.1002/9780470710449.ch8
SP  - 125-141
KW  - Laboratory diagnosis of addicting drugs
KW  - Clinical indications for drug testing
KW  - Methodology for Drug Testing
KW  - Ultraviolet spectroscopy
KW  - This feature is now incorporated in some chromatographic (HPLC) and capillary electrophoretic
KW  - gas chromatography-mass spectrometry (GC/MS)
KW  - Radio Immunoassay (RIA)
KW  - Enzyme-Multiplied Immunoassay Technique (EMIT)
KW  - Enzyme-Linked Immunosorbent Assay (ELISA)
KW  - Kinetic Interaction of Microparticles in Solution (KIMS)
PY  - 2009
AB  - Summary This chapter contains sections titled: Introduction Drug Testing Methodology for Drug Testing Sensitivity and Specificity Screening vs. Confirmation Methods Specimens Alcohol References
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - European Journal of Heart Failure
JA  - Eur J Heart Fail
VL  - 19
IS  - S1
SN  - 9780470740330
UR  - https://doi.org/10.1002/ejhf.833
DO  - doi:10.1002/ejhf.833
SP  - 5
EP  - 601
PY  - 2017
ER  - 

TY  - JOUR
TI  - HIGHLIGHTED POSTER SESSIONS
JO  - The Journal of Sexual Medicine
VL  - 6
IS  - s5
SN  - 9780470740330
UR  - https://doi.org/10.1111/j.1743-6109.2009.01608_2.x
DO  - doi:10.1111/j.1743-6109.2009.01608_2.x
SP  - 421
EP  - 428
PY  - 2009
ER  - 

TY  - JOUR
TI  - Program & Abstracts
JO  - Journal of Bone and Mineral Research
JA  - J Bone Miner Res
VL  - 17
IS  - S1
SN  - 9780470740330
UR  - https://doi.org/10.1002/jbmr.5650170102
DO  - doi:10.1002/jbmr.5650170102
SP  - S1
EP  - S502
PY  - 2002
ER  - 

TY  - JOUR
TI  - Abstract for POSTER presentation
JO  - International Journal of Urology
VL  - 17
IS  - s1
SN  - 9780470740330
UR  - https://doi.org/10.1111/j.1442-2042.2010.02649.x
DO  - doi:10.1111/j.1442-2042.2010.02649.x
SP  - A247
EP  - A383
PY  - 2010
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - BJU International
JA  - BJU Int
VL  - 116
IS  - S4
SN  - 9780470740330
UR  - https://doi.org/10.1111/bju.13339
DO  - doi:10.1111/bju.13339
SP  - 1
EP  - 27
PY  - 2015
ER  - 

TY  - JOUR
TI  - Basic Science Podium/Poster
JO  - Neurourology and Urodynamics
JA  - Neurourology and Urodynamics
VL  - 38
IS  - S1
SN  - 9780470740330
UR  - https://doi.org/10.1002/nau.23949
DO  - doi:10.1002/nau.23949
SP  - S6
EP  - S255
PY  - 2019
ER  - 

TY  - JOUR
TI  - Wednesday July 5, 2006 17:30–19:00 Hall 1 Schwarz Pharma & Valeant Pharmaceuticals International Satellite Symposium What's around the corner: AEDs in late development
JO  - Epilepsia
VL  - 47
IS  - s3
SN  - 9780470740330
UR  - https://doi.org/10.1111/j.1528-1167.2006.00715_90.x
DO  - doi:10.1111/j.1528-1167.2006.00715_90.x
SP  - 272
EP  - 272
PY  - 2006
AB  - 1 E. Ben-Menachem ( 1 Neurologkliniken, Sahlgrenska Universitetssjukhuset, Goteberg, Sweden ) Lacosamide is in Phase 3 of clinical development for the adjunctive treatment of epilepsy and neuropathic pain. Currently the mode of action (MOA) is under investigation since it has been previously demonstrated that lacosamide does not share a MOA with other currently marketed antiepileptic drugs (AEDs). The drug can be administered orally or intravenously. Results from pharmacokinetic studies suggest that lacosamide has a low potential for drug-drug interactions, and it appears that lacosamide has a minimal risk for affecting the pharmacokinetics of commonly prescribed concomitant AEDs for the treatment of epilepsy. In a double-blind, randomized, placebo-controlled, multicenter trial for the treatment of partial seizures (SP667), lacosamide was administered orally in doses of 200 mg, 400 mg and 600 mg divided in 2 daily doses. In this trial, lacosamide demonstrated a statistically significant reduction in seizure frequency over placebo. Moreover, the 50% responder rate (defined as patients with at least a 50% reduction in seizure frequency) was statistically significant. A further trial (SP616) investigated the safety, tolerability and pharmacokinetics of IV lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. The nature of AEs reported following 60- and 30 minute infusions of lacosamide was consistent with AEs reported following oral administration of lacosamide. Dose-related adverse events include dizziness, nausea, fatigue, ataxia, vision abnormal, diplopia, and nystagmus. The currently available results justify the further development of lacosamide for the treatment of epilepsy.
ER  - 

TY  - JOUR
AU  - Fame, Ryann M.
AU  - Cortés-Campos, Christian
AU  - Sive, Hazel L.
C7  - 1900186
TI  - Brain Ventricular System and Cerebrospinal Fluid Development and Function: Light at the End of the Tube
JO  - BioEssays
JA  - BioEssays
VL  - 42
IS  - 3
SN  - 9780470740330
UR  - https://doi.org/10.1002/bies.201900186
DO  - doi:10.1002/bies.201900186
SP  - 1900186
KW  - brain ventricles
KW  - cerebrospinal fluid
KW  - choroid plexus
KW  - epithelial relaxation
KW  - neural tube
KW  - neuroepithelium
KW  - neurological diseases
PY  - 2020
AB  - Abstract The brain ventricular system is a series of connected cavities, filled with cerebrospinal fluid (CSF), that forms within the vertebrate central nervous system (CNS). The hollow neural tube is a hallmark of the chordate CNS, and a closed neural tube is essential for normal development. Development and function of the ventricular system is examined, emphasizing three interdigitating components that form a functional system: ventricle walls, CSF fluid properties, and activity of CSF constituent factors. The cellular lining of the ventricle both can produce and is responsive to CSF. Fluid properties and conserved CSF components contribute to normal CNS development. Anomalies of the CSF/ventricular system serve as diagnostics and may cause CNS disorders, further highlighting their importance. This review focuses on the evolution and development of the brain ventricular system, associated function, and connected pathologies. It is geared as an introduction for scholars with little background in the field.
ER  - 

TY  - JOUR
TI  - PODIUM SESSIONS
JO  - The Journal of Sexual Medicine
VL  - 6
IS  - s5
SN  - 9780470740330
UR  - https://doi.org/10.1111/j.1743-6109.2009.01608_1.x
DO  - doi:10.1111/j.1743-6109.2009.01608_1.x
SP  - 403
EP  - 420
PY  - 2009
ER  - 
